SCHEMBL7540460

SCHEMBL7540460

COc1ccc(CS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
ALDH1A1 P00352 4/20 0.46
CA1 P00915 5/20 0.46
CA9 Q16790 5/20 0.46
CA12 O43570 3/20 0.46
CA5A P35218 1/20 0.46
CA14 Q9ULX7 1/20 0.46
KDM4E B2RXH2 1/20 0.44
ATM Q13315 1/20 0.44
LDHA P00338 1/20 0.43
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
MEN1 O00255 1/20 0.42
TNF P01375 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29665700 0.89 TUBB1 (0.43) SMN1; SMN2LMNAALDH1A1KDM4EMAPK1
SCHEMBL7535556 0.89 TUBB1 (0.43) SMN1; SMN2LMNAALDH1A1KDM4EMAPK1
SCHEMBL7534408 0.87 GAA (0.50) LMNATSHRMEN1GAAKMT2A
SCHEMBL24458142 0.81 TUBB1 (0.39) LMNAALDH1A1KDM4EMAPK1HTT
SCHEMBL29665751 0.81 TUBB1 (0.39) LMNAALDH1A1KDM4EMAPK1HTT
SCHEMBL24458182 0.80 HTT (0.41) LMNAALDH1A1KDM4EMAPK1MEN1
SCHEMBL7533749 0.79 CA12 (0.54) CA2SMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL7536230 0.79 HTT (0.41) LMNAALDH1A1KDM4EMAPK1HTT
SCHEMBL7533183 0.78 GAA (0.45) LMNATSHRMEN1GAAKMT2A
SCHEMBL7537091 0.76 CYP1A2 (0.47) LMNAALDH1A1TSHRMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 CA2 3895/4885SMN1; SMN2 4446/4885LMNA 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.